dengue vaccine
- Business Wire
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
− Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important…
Read More » - Health
Takeda and IDT Support Manufacturing of Johnson & Johnson’s COVID-19 Vaccine
Osaka, Japan: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and…
Read More »